Kbio Labs케이바이오랩스

Kbio Labs has shrunk sharply in price over the past year, while its filings show revenue growing but a large net loss in the first half of 2026.

Kbio Labs runs a life science distribution business and an ICT business rooted in video security. Trailing results to H1 2026 show revenue of ₩67.7B, a small operating profit of ₩1.5B, and a net loss of ₩14.9B. The share price closed at ₩2,925 on 26 October 2026, down 51% over one year, with a market value of ₩15.1B.

What stands out

• Trailing revenue of ₩67.7B is below the 2025 full-year figure of ₩87.3B, while the operating margin is thin at 2.2%.
• The net loss of ₩14.9B is far larger than the operating profit, and the data does not explain the gap.
• Balance sheet looks light: liabilities are 17.7% of equity, borrowings are ₩0.6B and cash is ₩2.5B.
• Price-to-book is 0.4 and there is no dividend; earnings-based valuation ratios are not available because earnings are negative.
• Foreign ownership fell from 4.9% to 1.6% over about 60 days, and foreign investors were net sellers over the last 20 days.

What to watch

• Trading halts were filed on 24 August and 18 September 2026; the data does not give the reason, so check the filings for details.
• The H1 2026 half-year report and any further filings on the net loss and the shareholder reports from August and September.
• News coverage is absent in the data, so there is no recent media context to weigh alongside the filings.